REFERENCES
- The Innate Immune Response To Infection, H Kaufmann, R Medzhitov, S Gordon. ASM Press, Washington, DC 2004; 465
- Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710–720, [PUBMED], [INFOTRIEVE], [CSA]
- Gallo R L, Nizet V. Endogenous production of antimicrobial peptides in innate immunity and human disease. Curr Allergy Asthma Rep 2003; 3: 402–409, [PUBMED], [INFOTRIEVE], [CSA]
- Beutler B. Innate immunity: an overview. Mol Immunol 2004; 40: 845–859, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hancock R E, Lehrer R. Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998; 16: 82–88, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389–395, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Brogden K A, Ackermann M, McCray P B, Jr, Tack B F. Antimicrobial peptides in animals and their role in host defences. Int J Antimicrob Agents 2003; 22: 465–478, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- van 't Hof W, Veerman E C, Helmerhorst E J, Amerongen A V. Antimicrobial peptides: properties and applicability. Biol Chem 2001; 382: 597–619, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers 2002; 66: 236–248, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Quinones-Mateu M E, Lederman M M, Feng Z, Chakraborty B, Weber J, Rangel H R, Marotta M L, Mirza M, Jiang B, Kiser P, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. Aids 2003; 17: F39–48, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sinha S, Cheshenko N, Lehrer R I, Herold B C. NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. Antimicrob Agents Chemother 2003; 47: 494–500, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wang W, Owen S M, Rudolph D L, Cole A M, Hong T, Waring A J, Lal R B, Lehrer R I. Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 2004; 173: 515–520, [PUBMED], [INFOTRIEVE]
- Yasin B, Wang W, Pang M, Cheshenko N, Hong T, Waring A J, Herold B C, Wagar E A, Lehrer R I. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol 2004; 78: 5147–5156, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gordon Y J, Huang L C, Romanowski E G, Yates K A, Proske R J, McDermott A M. Human cathelicidin (LL-37), a multi-functional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res 2005; 30: 385–394
- Hattenbach L O, Gumbel H, Kippenberger S. Identification of beta-defensins in human conjunctiva. Antimicrob Agents Chemother 1998; 42: 3332, [PUBMED], [INFOTRIEVE], [CSA]
- Haynes R J, Tighe P J, Dua H S. Antimicrobial defensin peptides of the human ocular surface. Br J Ophthalmol 1999; 83: 737–741, [PUBMED], [INFOTRIEVE], [CSA]
- McNamara N A, Van R, Tuchin O S, Fleiszig S M. Ocular surface epithelia express mRNA for human beta defensin-2. Exp Eye Res 1999; 69: 483–490, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- McDermott A M RR, Pei Y, Huang L, Proske R J. Defensin expression by the cornea: multiple signalling pathways mediate IL-1beta stimulation of hbD-2 expression by human corneal epithelial cells. Invest Ophthalmol Vis Sci 2003; 44: 1859–1865, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Narayanan S, Miller W L, McDermott A M. Expression of human beta-defensins in conjunctival epithelium: relevance to dry eye disease. Invest Ophthalmol Vis Sci 2003; 44: 3795–3801, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Huang L, Proske R J, McDermott A M. Expression of the peptide antibiotic LL-37/hCAP18 (Cathelicidin) by human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2003; 44: 1335, ARVO E-abstr
- Koczulla A R, Bals R. Antimicrobial peptides: current status and therapeutic potential. Drugs 2003; 63: 389–406, [PUBMED], [INFOTRIEVE]
- Yang D, Biragyn A, Hoover D M, Lubkowski J, Oppenheim J J. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol 2004; 22: 181–215, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Yang D, Biragyn A, Kwak L W, Oppenheim J J. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002; 23: 291–296, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Huang L, Proske R J, McDermott A M. Functional roles of the epithelial-derived antimicrobial-derived peptide LL-37 at the ocular surface. Invest Ophthalmol Vis Sci. 2004; 45: 4940, ARVO E-abstr
- Verhoef J. Antibiotic resistance: the pandemic. Adv Exp Med Biol 2003; 531: 301–313, [PUBMED], [INFOTRIEVE], [CSA]
- Shea K M. Antibiotic resistance: what is the impact of agricultural uses of antibiotics on children's health?. Pediatrics 2003; 112: 253–258, [PUBMED], [INFOTRIEVE]
- De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30: 115–133, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Yount N Y, Yeaman M R. Multidimensional signatures in antimicrobial peptides. Proc Natl Acad Sci USA 2004; 101: 7363–7368, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Daher K A, Selsted M E, Lehrer R I. Direct inactivation of viruses by human granulocyte defensins. J Virol 1986; 60: 1068–1074, [PUBMED], [INFOTRIEVE], [CSA]
- Zhang L, Yu W, He T, Yu J, Caffrey R E, Dalmasso E A, Fu S, Pham T, Mei J, Ho J J, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002; 298: 995–1000, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zhang L, Parente S, Harris S M, Falla T J. Broad spectrum antimicrobial and antiviral peptides for prevention of sexually-transmitted diseases. American Society of Microbiology, New Orleans, LA 2004; Abstract A-058
- Bradshaw J. Cationic antimicrobial peptides: issues for potential clinical use. BioDrugs 2003; 17: 233–240, [PUBMED], [INFOTRIEVE], [CSA]
- Yeaman M R, Yount N Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55: 27–55, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Andres E, Dimarcq J L. Cationic antimicrobial peptides: update of clinical development. J Intern Med 2004; 255: 519–520, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 1987; 84: 5449–5453, [PUBMED], [INFOTRIEVE], [CSA]
- Ge Y, MacDonald D L, Holroyd K J, Thornsberry C, Wexler H, Zasloff M. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother 1999; 43: 782–788, [PUBMED], [INFOTRIEVE], [CSA]
- Lamb H M, Wiseman L R. Pexiganan acetate. Drugs 1998; 56: 1047–1052, discussion 1053-1044[PUBMED], [INFOTRIEVE]
- Moore A. The big and small of drug discovery. Biotech versus pharma: advantages and drawbacks in drug development. EMBO Rep 2003; 4: 114–117
- Panyutich A, Shi J, Boutz P L, Zhao C, Ganz T. Porcine polymorphonuclear leukocytes generate extracellular microbicidal activity by elastase-mediated activation of secreted proprotegrins. Infect Immun 1997; 65: 978–985, [PUBMED], [INFOTRIEVE], [CSA]
- Giles F J, Rodriguez R, Weisdorf D, Wingard J R, Martin P J, Fleming T R, Goldberg S L, Anaissie E J, Bolwell B J, Chao N J, et al. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res 2004; 28: 559–565, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, Pajak T F, Fleming T R, Henke M, Bourhis J, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys 2004; 58: 674–681, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Donnelly J P, Bellm L A, Epstein J B, Sonis S T, Symonds R P. Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis 2003; 3: 405–412, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sader H S, Fedler K A, Rennie R P, Stevens S, Jones R N. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother 2004; 48: 3112–3118, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tan H H. Topical antibacterial treatments for acne vulgaris: comparative review and guide to selection. Am J Clin Dermatol 2004; 5: 79–84, [PUBMED], [INFOTRIEVE], [CSA]
- Kavanagh K, Dowd S. Histatins: antimicrobial peptides with therapeutic potential. J Pharm Pharmacol 2004; 56: 285–289, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chalekson C P, Neumeister M W, Jaynes J. Treatment of infected wounds with the antimicrobial peptide D2A21. J Trauma 2003; 54: 770–774, [PUBMED], [INFOTRIEVE]
- Chalekson C P, Neumeister M W, Jaynes J. Improvement in burn wound infection and survival with antimicrobial peptide D2A21 (Demegel). Plast Reconstr Surg 2002; 109: 1338–1343, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Levin M, Quint P A, Goldstein B, Barton P, Bradley J S, Shemie S D, Yeh T, Kim S S, Cafaro D P, Scannon P J, et al. Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000; 356: 961–967, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kristensen H. Plectasin—systematic applications of an antimicrobial peptide. American Society of Microbiology, New Orleans, LA 2004; Abstract D-125
- Scott M, Dullaghan E, Lee K, Chung W, Lowden M, Calvert B, Finlay B, Hancock B. Peptides enhance the activity of antibiotics by boosting the innate immune response. American Society of Microbiology, New Orleans, LA 2004; Abstract E-086
- Finlay B B, Hancock R E. Can innate immunity be enhanced to treat microbial infections?. Nat Rev Microbiol 2004; 2: 497–504, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kowalski R P, Dhaliwal D K, Karenchak L M, Romanowski E G, Mah F S, Ritterband D C, Gordon Y J. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003; 136: 500–505, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kowalski R P, Romanowski E G, Mah F S, Yates K A, Gordon Y J. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol. 2004; 138: 33–37, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mather R, Karenchak L M, Romanowski E G, Kowalski R P. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002; 133: 463–466, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Goldstein M H, Kowalski R P, Gordon Y J. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 1999; 106: 1313–1318, [PUBMED], [INFOTRIEVE], [CSA]
- Kowalski R P, Karenchak L M, Romanowski E G. Infectious disease: changing antibiotic susceptibility. Ophthalmol Clin North Am 2003; 16: 1–9, [PUBMED], [INFOTRIEVE], [CSA]
- Rhee M K, Kowalski R P, Romanowski E G, Mah F S, Ritterband D C, Gordon Y J. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 2004; 138: 226–230, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Garg P, Sharma S, Rao G N. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology 1999; 106: 1319–1323, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. J Antimicrob Chemother 1990; 26(Suppl F)165–179, [PUBMED], [INFOTRIEVE], [CSA]
- Coronado V G, Edwards J R, Culver D H, Gaynes R P. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. National Nosocomial Infections Surveillance (NNIS) System. Infect Control Hosp Epidemiol 1995; 16: 71–75, [CSA]
- Mannis M J. The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis. Trans Am Ophthalmol Soc 2001; 100: 243–271, [CSA]
- Midorikawa K, Ouhara K, Komatsuzawa H, Kawai T, Yamada S, Fujiwara T, Yamazaki K, Sayama K, Taubman M A, Kurihara H, et al. Staphylococcus aureus susceptibility to innate antimicrobial peptides, beta-defensins and CAP18, expressed by human keratinocytes. Infect Immun 2003; 71: 3730–3739, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Maisetta G, Batoni G, Esin S, et al. Activity of human beta-defensin 3 alone or combined with other antimicrobial agents against oral bacteria. Antimicrob Agents Chemother 2003; 47: 3349–3351, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rich D, Cullor J, Mannia M J, et al. The in vitro activity of defensins against pseudomonas in the presence of human tears. Invest Ophthalmol Vis Sci. 1990; 31(suppl), Abstract:2203
- Huang L, Narayanan S, Redfern R L, McDermott A M. Human tears inhibit antimicrobial activity of human beta-defensin-2 in vitro. Invest Ophthalmol Vis Sci. 2002; 43, ARVO E-abstr 82
- Cullor J S, Mannis M J, Murphy C J, Smith W L, Selsted M E, Reid T W. In vitro antimicrobial activity of defensins against ocular pathogens. Arch Ophthalmol 1990; 108: 861–864, [PUBMED], [INFOTRIEVE]
- Mannis M, Cullor J, Murphy C J. The use of defensins for the eradication of ocular pathogens. Invest Ophthalmol Vis Sci. 1989; 30(Suppl), Abstract: 363
- Mannis M, Schwab I R, Dries D. Defensins as preservative in corneal storage medium. Invest Ophthalmol Vis Sci. 1991; 32(Suppl), Abstract: 1062
- Murphy C J, Foster B A, Mannis M J, Selsted M E, Reid T W. Defensins are mitogenic for epithelial cells and fibroblasts. J Cell Physiol 1993; 155: 408–413, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Murphy C, Foster B, Mannis M J. The stimulation of ocular cell growth by defensins of human and rabbit origins. Invest Ophthalmol Vis Sci. 1989; 30(Suppl), Abstract: 149
- Gunshefski L, Mannis M J, Cullor J S, et al. In vitro antimicrobial activity of Shiva-11 against ocular pathogens. Cornea 1994; 13: 237–242, [PUBMED], [INFOTRIEVE]
- Gunshefski L, Macsai M, Granus V. Are synthetic cecropins (Shiva-11) effective against gentamicin resistant organism?. Invest Ophthalmol Vis Sci. 1993; 34(Suppl), Abstract: 850
- Murphy C, Jaynes J, Iwahashi C. The modulation of ocular cell growth by cecropins. Invest Ophthalmol Vis Sci. 1992; 33(Suppl), Abstract: 828
- Gruzensky W, Mannis M J, Schwab I R. The use of a cecropin analog, Hecate, against Acanthamoeba in vitro. Invest Ophthalmol Vis Sci. 1994; 35(Suppl), Abstract: 1337
- de Sousa L, Mannis M J, Schwab I R. The use of synthetic cepropin (D5C) in disinfecting contact lens solutions. CLAO J 1996; 22: 114–117, [CSA]
- Schwab I, de Sousa L B, Mannis M J. The use of defense peptides in corneal storage medica. Invest Ophthalmol Vis Sci. 1995; 36(Suppl), Abstract: 1017
- Nos-Barbera S, Portoles M, Morilla A, Ubach J, Andreu A, Paterson C A. Effect of hybrid peptides of cecropin A and mellitin in an experimental model of bacterial keratitis. Cornea 1997; 16: 101–106, [PUBMED], [INFOTRIEVE], [CSA]